Hunan Jiudian Pharmaceutical Co., Ltd.

Equities

300705

CNE1000034Z6

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-28 pm EDT 5-day change 1st Jan Change
36.81 CNY +1.63% Intraday chart for Hunan Jiudian Pharmaceutical Co., Ltd. +2.00% +10.77%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Elects Yang Yang and Fan Pengyun as Non-Independent Director CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd.(XSEC:300705) added to S&P Global BMI Index CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves 2022 Final Profit Distribution, Payable on May 15, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Cash Dividend for the Year of 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hunan Jiudian Pharma Wins Nod to Trial Anti-Inflammatory Patch MT
Jiudian Pharma Sees FY22 Profit to Rise Up to 33.7% MT
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 27 May 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021 CI
Nan Jiudian Pharmaceutical Announces Profit Distribution Plan for 2021 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Hunan Jiudian Pharmaceutical Co., Ltd. entered into an agreement to acquire Hunan Huiyang Information Technology Co., Ltd. from Duan Lixin and Duan Linong for CNY 8.56 million. CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves Final Dividend for the Year 2020 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2020 CI
Chart Hunan Jiudian Pharmaceutical Co., Ltd.
More charts
Hunan Jiudian Pharmaceutical Co Ltd is a company mainly engaged in research and development, production and sales of pharmaceutical preparations. The Company’s products are comprised of pharmaceutical preparations, raw materials, pharmaceutical excipients and plant extracts, including loxoprofen sodium gel ointment, ornidazole raw materials and preparations, dirithromycin raw materials and preparations, clindamycin phosphate tablets and so on. The products are used for the treatment of bacterial infections and anti-allergy. The Company sells its products to both domestic and international markets, including Europe, South Korea, India, Russia and South America.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
36.81
Average target price
-
Consensus

Annual profits - Rate of surprise